Citations

Clear

16280 citation(s) found for "Li, David".

With no lysine kinase 1 in hepatic stellate cells promotes mouse and human liver fibrosis through glycolytic triosephosphate isomerase 1
Firdaus, Zeba , Khanal, Shalil , Washington, Alexander M. , Solverson, Jasper K. , Doskey, Luke C. , Xiao, Yang, Yaqubi, Mehdi, Heimbach, Julie, Taner, Timuçin, Krueger, Eugene W., Shah, Vijay H., Starlinger, Patrick P., Schellenberg, Matthew J. , Heimbach, Julie K. , Pereyra, David , Heimbach, Julie K , Taner, Timucin , Krueger, Eugene W , Huang, Chou-Long , Starlinger, Patrick , Razidlo, Gina L , Schellenberg, Matthew , Kostallari, Enis , Washington, Alexander M , Pereyra, David , Taner, Timuçin , Krueger, Eugene W. , Huang, Chou‐Long , Shah, Vijay H , Starlinger, Patrick , Razidlo, Gina L. , Kostallari, Enis

Mayo Clinic

Hepatology | August 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001833 | PMID 42560363 Get It

Background and Aims: Liver fibrosis and cirrhosis are major global health burdens with limited treatments. Activated HSCs drive fibrosis through increased proliferation, migration, collagen deposition and glycolysis. The aim of this study is to elucidate the signaling events that lead to enhanced glycolysis, subsequent HSC activation, and liver fibrosis. Approach and Results: Utilizing a phospho-kinase array, we identified with no lysine kinase 1 (WNK1) as a new kinase in primary human HSCs activated by the profibrotic PDGF-B. PDGF-mediated glycolysis in HSCs was attenuated by the WNK1 selective inhibitor, WNK-IN-11, as measured by live-cell metabolic assay, Glifon-300 fluorescence, Glucose-Glo assay, and glucose transporter 1 immunofluorescence. To understand how WNK1 promotes glycolysis, we employed chemical genetics where an engineered WNK1 carrying threonine 301 to glycine mutation (WNK1 T301G ) mutant with a modified ATP pocket accommodated a specific ATP-γ-S analogue to thio-phosphorylate its substrates. Thio-phosphorylated proteins were analyzed by mass spectrometry, which identified the glycolytic protein, triosephosphate isomerase 1 (TPI1), as a novel WNK1 direct substrate. TPI1 interacted with WNK1 in condensates, membrane-less phase separation structures. Condensate disruption and knockdown of TPI1 or WNK1 reduced HSC proliferation and migration in vitro. In vivo, pharmacological or genetic WNK1 inhibition significantly attenuated liver fibrosis in carbon tetrachloride and high-fat, choline-deficient, L -amino acid diet mouse models. Finally, WNK1 inhibition reduced fibrogenesis ex vivo in human precision-cut liver slices. Conclusions: These findings identify WNK1 as a previously unrecognized kinase that promotes HSC activation and liver fibrosis via TPI1-mediated glycolysis, highlighting the WNK1-TPI1 axis as a potential therapeutic target.
Pyoderma Gangrenosum Phenotype Classification
Gaurav, Ahana , Gregoire, Samantha, Xia, Eric, McIntosh, Basil Alex, Alavi, Afsaneh, Bolognia, Jean, Cowen, Edward, Dominguez, Arturo R., Fivenson, David, Heffernan, Michael, Huang, William, Madigan, Lauren, Mauskar, Melissa, Nelson, Caroline, Patsatsi, Aikaterini , Pugliese, Douglas, Rojek, Nathan W. , Rosenbach, M., Shaigany, Sheila, Shinkai, Kanade , Smith, Gideon, SWERLICK, ROBERT, Ortega-Loayza, Alex, Gregoire, Samantha , Xia, Eric , Fernandez, Anthony P , Fivenson, David , Kaffenberger, B , Madigan, Lauren M. , Mauskar, Melissa , Means, Alexander D. , Pugliese, Douglas J., Rosenbach, Misha , Shaigany, Sheila , Smith, Gideon Piers , Swerlick, Robert A. , Ortega‐Loayza, Alex G. , Mostaghimi, Arash

Mayo Clinic

JAMA Dermatology | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamadermatol.2026.2285 | PMID 42555014 Get It

Importance Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by sterile ulcerative skin lesions. Multiple comorbidities and clinical features have been associated with PG, but no standardized guidelines exist for classifying PG phenotypes. Objective To develop an expert-established classification framework for PG phenotypes to inform treatment guidelines and future research endeavors. Evidence Review In this modified Delphi consensus study that included 23 board-certified dermatologists and Medical Dermatology Society members with expertise in PG, panelists completed 5 rounds of anonymous, iterative online surveys that were administered from December 2023 through July 2025. Before the beginning of the consensus exercise, a literature review was performed by nonvoting researchers to summarize existing data on PG clinical associations and comorbidities. A PubMed search from inception to September 2023 identified observational studies, narrative reviews, systematic reviews, and meta-analyses describing PG clinical associations and comorbidities that were published in English. Experts indicated their agreement with proposed PG phenotypes and disease modifiers with a consensus threshold of 70% or greater. Anonymous comments and aggregated results were presented in each subsequent round. In the final round, a framework of PG phenotypes and disease modifiers was proposed for agreement. Findings Twenty-three board-certified dermatologists and Medical Dermatology Society members with expertise in PG completed 5 rounds of iterative surveys. Consensus was reached on the final set of PG phenotypes and disease modifiers, with 83% of experts in agreement. PG phenotypes were overall classified into 2 major groups: PG with autoinflammatory syndromes and nonsyndromic PG. Nonsyndromic PG included 4 phenotypes: inflammatory bowel disease–associated PG, PG in association with hematologic cancers and blood dyscrasias, drug-induced PG, and other (including idiopathic) PG. Disease modifiers of PG phenotype presentations included involvement of special sites (head/neck, genitals, or peristomal skin) and extracutaneous manifestations. Conclusions and Relevance This expert-established, descriptive framework provides a standardized classification system for distinct PG phenotypes and its modifiers. This nomenclature may inform upcoming clinical guidelines and allow for consistency in reporting epidemiological research and outcomes among patients with PG.
Stereo-electroencephalography–guided radiofrequency thermocoagulation in patients with implanted neuromodulation devices: patient series
Freund, Brin , Vijayanarasimhan, Venkateshwaran , Safa, Adrian , Colella, Filippo Emmanuele , Sabsevitz, David S. , Perez‐Vega, Carlos , Middlebrooks, Erik H. , Byrne, Richard, Tatum, William O., Freund, Brin E , Ekert, Justyna, Colella, Filippo Emmanuele , Block, Cady, Perez-Vega, Carlos , Middlebrooks, Erik H , Ekert, Justyna O. , Block, Cady K. , Mirsattari, Seyed M. , Byrne, Richard, Tatum, William O.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | August 5, 2026 | Volume: 12 | Issue: 5 | Pages: No page available

10.3171/case26376 | PMID 42546343 Get It

BACKGROUND The authors aimed to evaluate the feasibility/safety of stereo-electroencephalography (SEEG) and SEEG-guided radiofrequency thermocoagulation (RFTC) in patients with drug-resistant epilepsy previously implanted with neuromodulation devices, using a retrospective cohort design evaluating patients treated at the Mayo Clinic Florida Epilepsy Center. OBSERVATIONS Nine patients (mean age 36.3 ± 10.9 years, 33% female) with prior implantation of neuromodulation devices were included. A vagus nerve stimulator was present in 8 of 9 patients, and 4 patients had undergone previous intracranial neuromodulation. Five patients underwent SEEG-RFTC. The mean SEEG monitoring duration was 6.5 ± 2.9 days. No intraoperative or procedural complications occurred, including hardware-related issues. No permanent or significant neurological/cognitive deficits occurred. One patient experienced transient postoperative neurological symptoms attributed to perilesional edema. Seizure reduction ranged from 50% to 75% following SEEG-RFTC. LESSONS SEEG and SEEG-RFTC are feasible in patients who have implanted neuromodulation devices, including intracranial implants. These procedures may be performed without interference with existing hardware and provide meaningful seizure reduction in highly refractory populations. Further studies with larger cohorts and longer follow-up are needed to better define efficacy and patient selection. https://thejns.org/doi/10.3171/CASE26376
Quantitative viscoelastic assessment of copolymer-in-oil tissue-mimicking phantoms using plane-wave and ARFI-induced shear wave elastography
Prado, Mariah Eugênia Cosso da Silva , Collazos-Burbano, David A. , Uliana, Joao Henrique, Brum, Javier , Carneiro, Antônio Adilton Oliveira , Pavan, Theo Z. , Prado, M E C S , Collazos-Burbano, D A , Uliana, J H , Brum, J , Urban, Matthew W , Carneiro, A A O , Pavan, T Z , Urban, Matthew W.

Mayo Clinic

Physics in Medicine & Biology | August 4, 2026 | Volume: 71 | Issue: 16 | Pages: 165015

10.1088/1361-6560/ae94da | PMID 42551492 Get It

Abstract Tissue-mimicking phantoms play a crucial role in evaluating new imaging modalities, simulating clinical scenarios, and ensuring the quality and reliability of imaging systems. Styrene–ethylene/butylene–styrene (SEBS) is an extremely stable and versatile material that has been recently used in ultrasound, elastography, and photoacoustic imaging across diverse applications. Despite its extensive use, a systematic viscoelastic characterization of different SEBS-based formulations reported in the literature, particularly using shear wave elastography (SWE), remains limited. To address this gap, this study investigates the viscoelastic properties of tissue-mimicking phantoms composed of SEBS, glycerol dispersions in SEBS gels, and mixtures of SEBS with low-density polyethylene (LDPE) in mineral oil, using gelatin phantoms as a reference for comparison. Viscoelastic parameters were estimated from shear wave velocity and attenuation dispersion curves using a Kelvin–Voigt model, based on SWE measurements with acoustic radiation force (ARF) excitation, shear plane-wave excitation, and complementary mechanical testing. SEBS-based phantoms exhibited broad, composition-dependent viscoelastic tunability. Increasing SEBS or LDPE content led to stiffer and more viscous responses, while glycerol primarily modulated viscosity and, at higher concentrations, also affected stiffness. Consistent and concordant values were obtained using both ARF and plane wave SWE techniques. The resulting stiffness (2–22 kPa) and viscosity (0.01–1.24 Pa⋅s) overlaps with the mechanical properties of several biological soft tissues, supporting use of these phantoms for SWE validation.
Beyond the Snapshot: Overcoming GES Limitations to Characterize Gastric Phenotypes and Therapeutic Responses Using a 6‐Day Ambulatory Wearable Monitor
Lacy, Brian E. , Cangemi, David J. , Axelrod, Lindsay , Axelrod, Steve , Navalgund, Anand , Cangemi, David

Mayo Clinic

Neurogastroenterology & Motility | August 4, 2026 | Volume: 38 | Issue: 8 | Pages: No page available

10.1111/nmo.70413 | PMID 42547873 Get It

ABSTRACT Background Gastric emptying scintigraphy (GES) is considered the standard for differentiating gastroparesis from functional dyspepsia and other foregut disorders characterized by nausea and vomiting but provides only a brief physiologic snapshot that may not accurately reflect daily function. We utilized a non‐invasive wireless patch system (WPS) to characterize multiday gastric myoelectrical activity, evaluate its relationship with GES, and assess changes following a therapeutic intervention. Methods Adults referred for GES for symptoms thought to represent gastroparesis were enrolled in a prospective study. Patients wore a WPS for up to 6 days, starting on the day of scintigraphy. Gastric myoelectrical activity was analyzed and categorized into relatively weak, relatively moderate, and relatively strong activity phenotypes. A subset of patients underwent repeat monitoring following individualized therapeutic interventions (e.g., anti‐emetics, proton pump inhibitors, lifestyle changes). Results Forty‐eight patients (mean age 44; 79% female) completed the study. GES identified delayed gastric emptying in 18%, rapid in 22%, and normal in 60% of subjects. During the 4‐h concurrent GES window, gastric activity in patients with delayed emptying was lower, but this difference did not reach statistical significance ( p = 0.08). When compared to the full multiday recording period, GES results showed no correlation with the myoelectric readings. Significant day‐to‐day variability was observed, both random and systemic. In the latter category, a “Test‐Day” dip was observed with gastric activity lowest on Day 1 (GES test day) and increasing significantly on subsequent days, stabilizing by Day 4 ( p < 0.001). Healthy control subjects recorded during normal daily routines showed no such day‐to‐day variation. In the retesting cohort, anti‐emetics produced robust increases in gastric amplitude, whereas PPIs showed minimal impact. Conclusions The WPS effectively captures distinct gastric phenotypes and quantifies physiologic responses to therapy in both gastric and intestinal regions, demonstrating its clinical utility as a robust tool for evaluating and managing foregut symptoms in real‐world settings. Importantly, the multiday WPS highlights significant day‐to‐day physiologic variability in gastric activity that extends beyond the single‐day GES ‘snapshot’.
Effect of time to palliative epilepsy surgery on outcomes
Crutcher, Robert M. , Horvat, David , Caraway, Avery R. , Arredondo, Kristen H. , Abel, Taylor J. , Agarwal, Nitin , Alexander, Allyson , Armstrong, Dallas , Auguste, Kurtis I. , Bernardo, Danilo , Bolton, Jeffrey , Bonda, David , Depositario‐Cabacar, Dewi F. , Groves, Aran, Hauptman, Jason S. , Knox, Andrew , Lin, Jenny, McGoldrick, Patricia E. , Miller, D. , Ostendorf, Adam P. , Pichon, Pilar, Reddy, Shilpa B. , Samanta, Debopam , Singh, Rani K. , Wagner, Janelle L. , Galán, Fernando , Perry, Μ. Scott , Ciliberto, Michael A. , Horvat, David E , Alexander, Allyson L , Armstrong, Dallas Michael , Depositario Cabacar, Dewi Frances , Eschbach, Krista , Gaillard, William D , Hauptman, Jason , Javarayee, Pradeep K , Karakas, Cemal , Knox, Andrew T , McGoldrick, Patricia E , Miller, Derryl J , Novotny, Edward J , Ostendorf, Adam P , Pichon, Pilar D , Reddy, Shilpa B , Samanta, Debopam , Singh, Rani K , Wagner, Janelle , Wolf, Steven , Wong-Kisiel, Lily C. , Galan, Fernando N , Perry, Michael Scott , Ciliberto, Michael A , Auguste, Kurtis I , Arredondo, Kristen H , Abel, Taylor J , Agarwal, Nitin , Bernardo, Danilo , Crutcher, Robert , Bonda, David , Depositario‐Cabacar, Dewi, Eschbach, Krista , Gaillard, William D. , Javarayee, Pradeep , Karakas, Cemal , Novotny, Edward J. , Wolf, Steven M. , Wong‐Kisiel, Lily C.

Mayo Clinic

Epilepsia | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70379 | PMID 42545811 Get It

Abstract Objective Epilepsy duration is a modifiable risk factor in the outcome of definitive epilepsy surgery; however, an analogous effect in palliative procedures has not been shown. We reviewed the Pediatric Epilepsy Surgery Database data for an association between epilepsy duration and seizure reduction in palliative procedures. Methods Patients enrolled between January 2018 and April 2025 who underwent their first epilepsy surgery with palliative intent with 6 months of follow‐up were included. Procedures included neuromodulation, corpus callosotomy, hemispherotomy, lesionectomy, and lobectomy where surgical intent was not seizure freedom. Outcomes of seizure freedom, 90% seizure reduction, and 50% seizure reduction were considered at 6–12 months and >12 months from surgery. Duration from epilepsy onset to surgery was compared for patients above and below each outcome threshold at each time point. Logistic regression analysis for the association between epilepsy duration and seizure reduction adjusted for potential confounders including procedure type, etiology, and other clinical factors. Logistic regression analysis was performed on the overall cohort and subgroups of patients with each procedure. Results A total of 588 patients were included. Initial univariate analysis suggested that epilepsy duration at time of surgery was significantly associated with seizure freedom and 90% seizure reduction at both 6–12 months and >12 months. After adjusting for confounders, only seizure freedom at >12 months was significantly associated with duration of epilepsy. When individual procedures were considered, only lobectomy was sensitive to duration of epilepsy in multivariate analysis, with significant impacts on >50% and >90% seizure reduction at >12 months. Lesional epilepsy predicted seizure freedom at >12 months. Neuromodulation and corpus callosotomy were less likely to achieve seizure reduction than other procedures. Significance We did not find an association between early epilepsy surgery and seizure reduction. This reflects the heterogeneity of our population, including different types of surgical procedures and lesional and nonlesional epilepsies.
WSB1-Mediated PSMA Ubiquitination Promotes Enzalutamide-Induced Neuroendocrine-like Transition in Patient-Derived Prostate Cancer Spheroids
Jung, Dawa, Kendi, A. Tuba , Woodrum, David A. , In, Myung‐Ho , Bilgin, Gokce Belge , Johnson, Derek R. , Kim, Eun-Joo, Chung, Jin Ook , Park, Seon-Young , Curran, Geoffry L., Lowe, Val J. , Lee, Seung Baek , Kendi, A Tuba , Adamo, Daniel A. , In, Myung-Ho , Belge Bilgin, Gokce , Johnson, Derek R , Horn, Ian M, Lowe, Val J , Lee, Seung Baek , Thompson, Scott M. , Horn, Ian M. , Curran, Geoffry L.

Mayo Clinic

International Journal of Molecular Sciences | August 3, 2026 | Volume: 27 | Issue: 15 | Pages: 6899

10.3390/ijms27156899 | PMID 42589556 Get It

Long-established prostate cancer cell lines provide limited insight into how contemporary early prostate cancer evolves into drug-resistant and neuroendocrine-like refractory disease. Patient-derived three-dimensional (3D) ex vivo models may better preserve this transition. Here, we found that 8 of 10 magnetic resonance imaging-guided biopsy specimens from patients with early-stage prostate cancer generated sustained 3D tumor spheroid cultures. After 12 weeks of enzalutamide selection, only one patient-derived culture acquired a resistant phenotype with treatment-emergent neuroendocrine prostate cancer (t-NEPC)-like features, including increased chromogranin A (CgA) and synaptophysin (SYP); reduced androgen receptor (AR), prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA); and conversion from compact spheroids into irregular resistant aggregates. During this transition, WD repeat and SOCS box-containing protein 1 (WSB1) increased, whereas PSMA progressively decreased. WSB1 silencing restored PSMA, AR, and PSA expression and reduced neuroendocrine-associated features. A similar WSB1 dependency was observed in enzalutamide-resistant LNCaP cells, the castration-resistant prostate cancer model 22Rv1, and the neuroendocrine/small-cell prostate cancer model NCI-H660. Mechanistically, WSB1 functioned as a SOCS box-dependent E3 ubiquitin ligase adaptor that promoted PSMA ubiquitination and degradation. SOCS box deletion or T380A mutation impaired this process, while Aurora kinase A (AURKA) inhibition reduced WSB1-dependent PSMA ubiquitination. WSB1 depletion, AURKA inhibition with alisertib, and combined AURKA inhibition with EZH2 suppression reduced resistant aggregate growth and increased apoptosis-associated markers in patient-derived enzalutamide-resistant neuroendocrine-like spheroids and related models. These findings nominate the AURKA–WSB1–PSMA axis as a therapeutic vulnerability in refractory prostate cancer.
High prevalence of iron deficiency among daratumumab‐treated newly diagnosed multiple myeloma patients
Hwa, Yi L. , Kumar, Shaji , Kapoor, Prashant , Gertz, Morie A. , Lacy, Martha Q. , Go, Ronald S. , Warsame, Rahma , Hobbs, Miriam, Fonder, Amie , Hayman, Suzanne R. , Kourelis, Taxiarchis , Kyle, Robert A. , Hwa, Yi L , Pak, Karen, Gertz, Morie A , Dingli, David D, Go, Ronald S , Leung, Nelson , Fonder, Amie L, Cook, Joselle M , Binder, Moritz , Rajkumar, S Vincent , Muchtar, E , Jevremović, Dragan , Visram, Alissa , Dingli, David , Buadi, Francis K. , Leung, Nelson , Gonsalves, Wilson I. , Rogers, Michelle, Cook, Joselle , Binder, Moritz , Rajkumar, S. Vincent , Dispenzieri, Angela , Muchtar, Eli

Mayo Clinic

British Journal of Haematology | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70697 | PMID 42543782 Get It

Summary Iron deficiency (ID) is often overlooked in patients with haematological malignancies due to other potential aetiologies. Daratumumab, an anti‐cluster of differentiation 38 (anti‐CD38) monoclonal antibody, is commonly used for treating multiple myeloma (MM) in the upfront and relapsed/refractory settings. Although anaemia is a common haematological toxicity associated with daratumumab, the contribution of ID in MM patients has not been systematically investigated. We conducted a retrospective case–control study to evaluate the prevalence of ID in newly diagnosed MM (NDMM) patients. Cases were patients receiving daratumumab, ixazomib, lenalidomide and dexamethasone (Dara‐IRD, n = 55). We compared this group with an age‐ and sex‐matched cohort of patients with NDMM who received bortezomib, lenalidomide and dexamethasone (VRD, n = 20) as induction therapy. At 1‐year, nearly 50% of Dara‐IRD‐treated patients met the criteria for ID (ferritin <30 mcg/L) compared with none of the VRD‐treated controls. All Dara‐IRD‐treated patients had a decrease in ferritin at 1‐year from baseline compared with only 45% of VRD‐treated patients. These findings identify a marked clinical signal of ID among NDMM patients receiving daratumumab‐based treatment. Although the study design does not establish causality or exclude regimen‐related confounding, it highlights the need for increased awareness of the importance of monitoring iron status in MM patients treated with daratumumab‐containing regimens.
Monoclonal gammopathy of clinical significance: a guide for nephrologists
Hofmann, Patrick , Rennke, Helmut G, Schwotzer, Rahel , Sykes, David B, Leung, Nelson , Leung, Nelson , Shah, Sujal I. , Rennke, Helmut G. , Sykes, David B. , Chowdhury, Raad

Mayo Clinic

Nephrology Dialysis Transplantation | August 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ndt/gfag173 | PMID 42545758 Get It

Abstract Monoclonal gammopathy of undetermined significance (MGUS) is commonly encountered in older individuals. MGUS, by definition, is a benign finding where an expanded population of clonal plasma and B-cells produces a monoclonal antibody that is a biologically inactive. Even in patients with overt plasma cell neoplasms such as multiple myeloma, the monoclonal antibody is often a marker of disease burden but not pathogenic except in light chain cast nephropathy. However, there is a growing recognition that, in rare cases, clonal cells and/or monoclonal gammopathy not meeting criteria for hematologic malignancy can be pathogenic drivers of disease. These MGUS syndromes have been termed monoclonal gammopathies of clinical significance (MGCS), a larger umbrella under which sits the monoclonal gammopathies of renal significance (MGRS). In this review, we focus on MGCS entities beyond standard MGRS and provide a mechanism-based classification centered on the pathogenic nature of the paraprotein rather than on clonal disease burden. We highlight MGCS entities of relevance to nephrologists, including POEMS syndrome, TEMPI syndrome, monoclonal gammopathy-associated systemic capillary leak syndrome, and hematologic autoantibody-mediated disorders. Awareness and recognition of these rare processes are ultimately essential for accurate diagnosis and patient management.